The Textbook of Pharmaceutical Medicine / Edition 5

The Textbook of Pharmaceutical Medicine / Edition 5

by John P. Griffin
     
 

ISBN-10: 0727918400

ISBN-13: 9780727918406

Pub. Date: 02/28/2006

Publisher: Wiley

This book reviews the latest research and trends in the field, with sections on research and development, medical department issues, regulatory aspects, and pharmacoeconomic and other issues. Chapter topics include the supply of unlicensed medicines for patient use, the safety of medicines, the US Food and Drug Administration's role in drug development, and regulatory

Overview

This book reviews the latest research and trends in the field, with sections on research and development, medical department issues, regulatory aspects, and pharmacoeconomic and other issues. Chapter topics include the supply of unlicensed medicines for patient use, the safety of medicines, the US Food and Drug Administration's role in drug development, and regulatory and clinical trail systems in Japan. Other topics include medical marketing, toxicity testing, clinical pharmacokinetics, and medical statistics. Griffin is a visiting professor at the University of Surrey Postgraduate Medical School. Annotation ©2003 Book News, Inc., Portland, OR

Product Details

ISBN-13:
9780727918406
Publisher:
Wiley
Publication date:
02/28/2006
Edition description:
REV
Pages:
880
Product dimensions:
7.00(w) x 10.00(h) x 1.90(d)

Table of Contents

Part I: Research and development.

Introduction: the development of pharmaceutical medicine as a specialty (Susan Bews and Huw Jones).

1 Discovery of new medicines (Anand S Dutta).

2 Pharmaceutical development (Gavin Halbert).

3 Preclinical safety testing (Lutz Mueller and David J Tweats).

4 Exploratory development (John Posner).

5 Clinical pharmacokinetics (Paul Rolan and Valeria Rolan).

6 Purpose and design of clinical trials (Roger A Yates and Steve Warrington).

7 Conduct of clinical trials: good clinical practice (Roger A Yates and Steve Warrington).

8 Medical statistics (Andrew P Grieve).

9 Development of medicines: full development (Alan G Davies and Peter D Stonier).

Part II: Medical department issues.

10 The medical department (Peter D Stonier).

11 Medical marketing (David Galloway).

12 Information and promotion (Charles de Wet).

13 The supply of unlicensed medicines for particular patient use (Ian Dodds-Smith, Amanda Wearing and John O'Grady).

14 Ethics of human experimentation (Duncan Vere).

15 Legal and ethical issues relating to medicinal products (David Marks, Nick Beckett, Sarah Hanson and Shuna Mason).

16 The safety of medical products (A. Peter Fletcher and Susan Shaw).

Part III: Regulatory aspects.

17 History of drug regulation in the United Kingdom (John P Griffin and Rashmi R Shah).

18 Regulation of human medicinal products in the European Union (John P Griffin and Rashmi R Shah).

19 Paediatric regulation (Heike Rabe).

20 European regulation of medical devices (Christopher JS Hodges).

21 Technical requirements for registration of pharmaceuticals for human use: the ICH process (Dean W G Harron).

22 The regulation of drug products by the United States Food and Drug Administration (Peter Barton Hutt).

23 The US FDA in the drug development, evaluation and approval process (Richard N Spivey, Judith K Jones, William Wardell and William Vodra).

24 Past evolution and future prospects of the Pharma Industry and its regulation in the USA (William Wardell, William Vodra, Judith K Jones and Richard N Spivey).

25 Regulatory and clinical trial systems in Japan (Yuichi Kubo).

26 The regulation of therapeutic products in Australia (Janice Hirshorn and Deborah Monk).

27 Pharmaceutical medicine in emerging markets (N. Shreeharan).

Part IV: Pharmacoeconomic and other issues.

28 Economics of healthcare (Carole Bradley-Kennedy and Jane R Griffin).

29 Controls on NHS medicines prescribing and expenditure in the UK (a historical perspective) with some international comparisons (John P Griffin and Jane R Griffin).

30 Due diligence and the pharmaceutical physician (Geoff Barker).

Appendix 1 Declaration of Helsinki.

Appendix 2 Code of Practice for the Pharmaceutical Industry.

Appendix 3 Guidelines and Documentation for Implementation of Clinical Trials.

Appendix 4 Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001.

Customer Reviews

Average Review:

Write a Review

and post it to your social network

     

Most Helpful Customer Reviews

See all customer reviews >